Home › drug
 

Keywords :   


Tag: drug

Friendly takeover offer for Patheon values contract drug maker at US$1.4 billion

2013-11-20 01:46:45| IT Services - Topix.net

Patheon Inc. has received a friendly going-private proposal that values the TSX-listed company at about US$1.4 billion, more than 50 per cent above its recent market price.

Tags: offer friendly values drug

 

Workplace drug use on the decline

2013-11-19 04:38:51| Biotech - Topix.net

The number of U.S. workers who test positive for drugs has fallen sharply since 1988, The Wall Street Journal reports.

Tags: drug decline workplace workplace drug

 
 

Novo Nordisk hemophilia drug moves closer to approval in Japan

2013-11-18 19:29:48| Biotech - Topix.net

NovoEight, a hemophilia drug made by Denmark's Novo Nordisk, is a step closer to marketing approval in Japan after it passed a review by the country's drugs committee.

Tags: japan drug approval novo

 

GlaxoSmithKline's asthma drug Relvar approved in Europe

2013-11-18 15:25:07| Biotech - Topix.net

GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Europe to treat both asthma and chronic obstructive pulmonary disease , confirming an endorsement from regulators in September.

Tags: europe approved drug asthma

 

Mercks New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL (posaconazole) Receives FDA Priority Review

2013-11-18 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Marketing Authorization Application also Filed with the European Medicines Agency WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous (IV) solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Language: English Contact: MerckMedia Contacts:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application drug priority

 

Sites : [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] next »